 NuCana has been on my watch list over the past year due to its intriguing ProTide platform technology, which could generate multiple oncology drugs that can outperform the current standard of care. The share price has been under pressure since January and has been ground into an attractive valuation. I believe there is an astonishing risk-reward at these prices. 